Showing 5341-5350 of 9772 results for "".
- Vial to Host Advisory Boardhttps://practicaldermatology.com/news/vial-to-host-advisory-board/2461038/Vial is hosting an Advisory Board with leading research sites to discuss the challenges in clinical research. Launched in conjunction with the 2022 Winter Clinical Dermatology conference, the meeting will focus on improving speed and quality of trials in dermatology. The Vial executive
- Vial Launches Dermatology CROhttps://practicaldermatology.com/news/vial-launches-dermatology-cro/2461031/Vial has launched the Vial Dermatology CRO, dubbing it “The CRO Built for Sponsors.” The San Francisco-based company will rely on a clinic network of more than 35 dermatology clinics across the country to re
- FDA Accepts Arcutis Biotherapeutics’ NDA for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-arcutis-biotherapeutics-nda-for-roflumilast-cream-for-adults-and-adolescents-with-plaque-psoriasis/2461018/The FDA accepted Arcutis Biotherapeutics’ new drug application (NDA) for roflumilast cream for the treatment of psoriasis in adults and adolescents. The FDA assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2022. “With the FDA c
- NKTR-358 Demonstrates Proof of Concept in ADhttps://practicaldermatology.com/news/nktr-358-demonstrates-proof-of-concept-in-ad/2461011/Nektar Therapeutics and its partner Eli Lilly & Company’s NKTR-358 (LY3471851), a novel T regulatory (Treg) cell stimulator, demonstrated proof of concept in a Phase 1b study of patients with moderate-to-severe atopic dermatitis. The findings were presented at Eli Lilly&n
- FDA Accepts NDA for Boehringer Ingelheim’s Spesolimab for GPPhttps://practicaldermatology.com/news/fda-accepts-nda-for-boehringer-ingelheims-spesolimab-for-gpp/2461010/FDA has accepted a Biologics License Application (BLA) and granted Priority Review for Boehringer Ingelheim’s spesolimab for the treatment of generalized pustular psoriasis (GPP) flares. The FDA has granted spesolimab Orphan Drug Designation for the treatment of GPP, and Bre
- NPF Launches Multimedia Resource Center for Health Care Providers Caring for Individuals with Psoriatic Diseasehttps://practicaldermatology.com/news/npf-launches-multimedia-resource-center-for-health-care-providers-caring-for-individuals-with-psoriatic-disease/2461008/The National Psoriasis Foundation (NPF) is committed to offering innovative ways for health care providers (HCPs) to stay up-to-date on the latest news and research related to psoriatic disease. As part of its five-year strategic plan to improve health outcomes for all living with the disease, in
- Alastin to be Acquired by Galdermahttps://practicaldermatology.com/news/alastin-to-be-acquired-by-galderma/2460997/Galderma is set to acquire Alastin Skincare®, Inc. The world’s largest independent dermatology company has signed a definitive agreement to acquire the specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. Financial
- FDA Clears New Lifting Indications for Sofwavehttps://practicaldermatology.com/news/new-indications-for-sofwave/2460996/Sofwave is now U.S. Food and Drug Administration (FDA)-cleared for lifting the eyebrow and lifting lax submental tissue and neck tissue in people aged 22 or older. In addition, the Sofwave system featuring the Company's proprietary Superb TM (Synchronous Ultrasound Parallel Be
- Novel Lyme Vaccine Shows Promise in Early Researchhttps://practicaldermatology.com/news/novel-lyme-vaccine-shows-promise-in-early-research/2460994/Yale University researchers have developed a novel vaccine that in guinea pigs offers protection against infection by the bacterium that causes Lyme disease and may also combat other tick-borne diseases, they report in the journal Science Translational Medicine. Instead of trig
- New International Recommendations for Treating Acne Scars with Energy-Based Deviceshttps://practicaldermatology.com/news/new-international-recommendations-for-treating-acne-scars-with-energy-based-devices/2460990/Energy-based devices are the first-line treatments for a variety of acne scars, according to new international consensus recommendations published in Lasers in Surgery and Medicine. For the first time